2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162164
    Neuroprotective agent 3 130995-63-0 98%
    Neuroprotective agent 3 (Compound 21a) is an antioxidant that exhibits neuroprotective effects. Neuroprotective agent 3 significantly increases neuronal viability and induces neuroprotection, as well as improves neurological deficit scores in an in vivo model of transient cerebral ischemia.
    Neuroprotective agent 3
  • HY-162165
    Neuroprotective agent 4 161095-11-0 98%
    Neuroprotective agent 4 (compound 24a) is a novel and effective small molecule antioxidant. Neuroprotective agent 4 has a neuroprotective effect. Neuroprotective agent 4 can be used in the study of ischemic stroke and related diseases.
    Neuroprotective agent 4
  • HY-162167
    COX-1-IN-1 1369503-03-6 98%
    COX-1-IN-1 (compound 15a) is a selective inhibitor for cyclooxygenase (COX), with IC50s of 0.23 μM (COX-1) and >50 μM (COX-2), selective index (COX-2 IC50/COX-1 IC50) is 217. COX-1-IN-1 inhibits platelet aggregation.
    COX-1-IN-1
  • HY-162232
    mGluR2 agonist 1 3042819-62-2 98%
    mGluR2 agonist 1 (Compound 5b) is a potent and selective metabotropic glutamate 2 receptor (mGluR) agonist with an EC50 of 82 nM. mGluR2 agonist 1 can be used for the research of central nervous system (CNS) diseases.
    mGluR2 agonist 1
  • HY-162246
    Nav1.8-IN-5 3023247-79-9 98%
    Nav1.8-IN-5 (Example 1) is a voltage-gated sodium channel Nav1.8 inhibitor. Nav1.8-IN-5 can be used for Nav1.8-mediated diseases, such as pain and pain-related disorders, as well as cardiovascular diseases (such as atrial fibrillation) research.
    Nav1.8-IN-5
  • HY-162258
    AChE-IN-57 98%
    AChE-IN-57 (compound 5b(SP-2)) is a potent AChE inhibitor. AChE-IN-57 improves cognitive defects. AChE-IN-57 restores the biochemical mediators and inhibits reactive oxygen and nitrogen species implicated in the neuroinflammation mechanism. AChE-IN-57 has the potential for the research of Alzheimer.
    AChE-IN-57
  • HY-162277
    BuChE-IN-10 98%
    BuChE-IN-10 (compound 7p) is an inhibitor of BuChE (eqBuChE IC50 = 4.68 nM, huBuChE IC50 = 9.12 nM). BuChE-IN-10 has anti-neuroinflammatory activity and exhibits high BBB permeability.
    BuChE-IN-10
  • HY-162303
    C175-0062 686736-69-6 98%
    C175-0062 is a monoamine oxidase B (MAO-B) inhibitor. C175-0062 can be used for the research of neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS).
    C175-0062
  • HY-162304
    MAGL-IN-14 2770967-04-7 98%
    MAGL-IN-14 (compound 2) is a potent inhibitor of MAGL, with IC50 of 0.00289 μM and 0.002 μM in HEK293 and PC3 cells, respectively.
    MAGL-IN-14
  • HY-162305
    MAGL-IN-15 2770967-08-1 98%
    MAGL-IN-15 (Compound 6) is a MAGL inhibitor that can be used in the research of diseases and disorders related to the regulation of endocannabinoid system signaling activities.
    MAGL-IN-15
  • HY-162315
    MAGL-IN-16 98%
    MAGL-IN-16 (compound 27) is an oral active, selective and reversible MAGL inhibitor with the IC50 value of 10.3 nM. MAGL-IN-16 can increase the level of 2-AG and shows antidepressant effect in mouse depressed model caused by chronic restraint stress.
    MAGL-IN-16
  • HY-162330
    HDAC6-IN-36 98%
    HDAC6-IN-36 (compound 11d) is an inhibitor of HDAC6 with IC50 value of 8.64 nM. HDAC6-IN-36 induces neurite outgrowth of PC12 cells without producing toxic effects.
    HDAC6-IN-36
  • HY-162336
    Casein kinase 1δ-IN-15 2765264-27-3 98%
    Casein kinase 1δ-IN-15 is an inhibitor for casein kinase 1 (CK1δ), with an IC50 of 0.045 μM.
    Casein kinase 1δ-IN-15
  • HY-162338
    BChE-IN-29 3034669-76-3 98%
    BChE-IN-29 (Compound 27a) is a BChE inhibitor (IC50: 0.078 μM and 0.74 μM for BChE and AChE respectively). BChE-IN-29 has anti-inflammatory activity and can be used for research of AD.
    BChE-IN-29
  • HY-162339
    BChE-IN-30 3034669-94-5 98%
    BChE-IN-30 (compound (R)-37a) is a BChE inhibitor (IC50: 5 nM) with anti-inflammatory activity and low toxicity. BChE-IN-30 can improve cognitive deficits induced by scopolamine and Aβ1-42 peptide and can be used in the study of late-stage AD.
    BChE-IN-30
  • HY-162347
    Nav1.7-IN-13 2776235-57-3 98%
    Nav1.7-IN-13 (compound 3g) is a sodium channel inhibitor that significantly inhibits Veratridine (HY-N6691)-induced neuronal activity. Nav1.7-IN-13 inhibits total Na+ current in DRG neurons in a concentration-dependent manner; slows down the activation of Navs. Nav1.7-IN-13 significantly alleviated mechanical pain behavior in a rat model of nerve injury (SNI) and had analgesic activity.
    Nav1.7-IN-13
  • HY-162363
    MD6a 98%
    MD6a is a melatonin derivative with inhibitroy activity towards PARP-1, which maintains proteins hemostasis and improves mitochondrial function through TOR/HSF-1 signaling. MD6a a neuroprotective effect.
    MD6a
  • HY-162364
    p38-α MAPK-IN-7 98%
    p38-α MAPK-IN-7 (compound 4) is a p38α-MAPK inhibitor with an IC50 value of 98.7 nM. p38-α MAPK-IN-7 protects neuronal cells from dexamethasone-induced ROS production.
    p38-α MAPK-IN-7
  • HY-162388
    TIM-098a 98%
    TIM-098a is a selective AAK1 inhibitor with an IC50 of 0.24 µM. TIM-098a has no inhibitory activity against CaMKK isoforms. TIM-098a inhibits AAK1-regulated endocytosis by suppressing AAK1 kinase activity.
    TIM-098a
  • HY-162491
    JR-6 98%
    JR-6 is a Gi/o pathway biased and muscarinic M2 selective partial agonist.
    JR-6
Cat. No. Product Name / Synonyms Application Reactivity